JP2024536341A - 自閉症スペクトラム障害を有する対象を治療するための方法及び製品 - Google Patents

自閉症スペクトラム障害を有する対象を治療するための方法及び製品 Download PDF

Info

Publication number
JP2024536341A
JP2024536341A JP2024520543A JP2024520543A JP2024536341A JP 2024536341 A JP2024536341 A JP 2024536341A JP 2024520543 A JP2024520543 A JP 2024520543A JP 2024520543 A JP2024520543 A JP 2024520543A JP 2024536341 A JP2024536341 A JP 2024536341A
Authority
JP
Japan
Prior art keywords
solid
ticagrelor
odt
odf
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024520543A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024536341A5 (cg-RX-API-DMAC10.html
Inventor
ジサペル，ナヴァ
ラウドン，モシェ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurim Pharmaceuticals 1991 Ltd
Original Assignee
Neurim Pharmaceuticals 1991 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharmaceuticals 1991 Ltd filed Critical Neurim Pharmaceuticals 1991 Ltd
Publication of JP2024536341A publication Critical patent/JP2024536341A/ja
Publication of JP2024536341A5 publication Critical patent/JP2024536341A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024520543A 2021-10-04 2022-10-03 自閉症スペクトラム障害を有する対象を治療するための方法及び製品 Pending JP2024536341A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163251935P 2021-10-04 2021-10-04
US63/251,935 2021-10-04
PCT/IB2022/059429 WO2023057879A1 (en) 2021-10-04 2022-10-03 Methods and products for treating subjects with autism spectrum disorders

Publications (2)

Publication Number Publication Date
JP2024536341A true JP2024536341A (ja) 2024-10-04
JP2024536341A5 JP2024536341A5 (cg-RX-API-DMAC10.html) 2025-01-14

Family

ID=83688729

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024520543A Pending JP2024536341A (ja) 2021-10-04 2022-10-03 自閉症スペクトラム障害を有する対象を治療するための方法及び製品

Country Status (16)

Country Link
US (1) US11878016B2 (cg-RX-API-DMAC10.html)
EP (1) EP4412616A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024536341A (cg-RX-API-DMAC10.html)
KR (1) KR20240089377A (cg-RX-API-DMAC10.html)
CN (1) CN118265521A (cg-RX-API-DMAC10.html)
AU (2) AU2022358998B2 (cg-RX-API-DMAC10.html)
CA (1) CA3232273A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024000992A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024005762A2 (cg-RX-API-DMAC10.html)
CR (1) CR20240184A (cg-RX-API-DMAC10.html)
EC (1) ECSP24033949A (cg-RX-API-DMAC10.html)
IL (1) IL311681B2 (cg-RX-API-DMAC10.html)
MX (1) MX2024004150A (cg-RX-API-DMAC10.html)
PE (1) PE20241338A1 (cg-RX-API-DMAC10.html)
TW (1) TW202322821A (cg-RX-API-DMAC10.html)
WO (1) WO2023057879A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025051399A1 (en) * 2023-09-10 2025-03-13 Dafechem Ltd Liquid ticagrelor formulation
WO2025247961A1 (en) * 2024-05-31 2025-12-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Lpa-lpar signaling as a therapeutic target or diagnostic tool for brain diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9233966B2 (en) * 2012-04-05 2016-01-12 Dr. Reddy's Laboratories Limited Preparation of ticagrelor
CN104971042B (zh) 2014-04-04 2018-01-05 中国医学科学院医药生物技术研究所 替格瑞洛口服自微乳组合物
CN104434931A (zh) * 2014-11-06 2015-03-25 南京华威医药科技开发有限公司 含替格瑞洛和阿司匹林的复方口服固体剂及其制备方法
CN105669674A (zh) * 2014-11-21 2016-06-15 重庆圣华曦药业股份有限公司 一种替卡格雷新晶型及其在药物制剂中的应用
RS66536B1 (sr) * 2016-04-21 2025-03-31 Astrazeneca Ab Tablete za oralno raspadanje
CN105943515A (zh) * 2016-06-24 2016-09-21 山东鲁抗医药股份有限公司 一种替格瑞洛口腔崩解片及其制备方法
CN108078944A (zh) * 2016-11-22 2018-05-29 重庆植恩药业有限公司 含有替格瑞洛的固体组合物及其制备方法
TR201617983A2 (tr) * 2016-12-07 2018-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Ti̇cagrelorun kati oral farmasöti̇k bi̇leşi̇mleri̇
US10614684B2 (en) * 2017-01-31 2020-04-07 The United States Government As Represented By The Treatment of kidney diseases associated with elevated AVP
EP3700525A4 (en) * 2017-10-27 2021-08-25 Beyond Barriers Therapeutics, Inc. IMPROVED PROVISION OF ANTIOXIDANTS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES WITH OXIDATIVE STRESS
KR102007731B1 (ko) * 2018-02-12 2019-08-06 충남대학교산학협력단 티카그렐러를 포함하는 자가 미세유화 약물전달시스템 조성물 및 이의 제조방법
CN110876750A (zh) * 2018-09-06 2020-03-13 江苏恒瑞医药股份有限公司 一种含有替格瑞洛或其可药用盐的缓释组合物
CA3179635A1 (en) * 2020-05-29 2021-12-02 Boulder Bioscience Llc Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane

Also Published As

Publication number Publication date
IL311681B1 (en) 2025-10-01
KR20240089377A (ko) 2024-06-20
IL311681B2 (en) 2026-02-01
CR20240184A (es) 2024-07-03
MX2024004150A (es) 2024-04-22
EP4412616A1 (en) 2024-08-14
TW202322821A (zh) 2023-06-16
CO2024005762A2 (es) 2024-05-30
US20230105540A1 (en) 2023-04-06
CA3232273A1 (en) 2023-04-13
CL2024000992A1 (es) 2024-09-13
US11878016B2 (en) 2024-01-23
CN118265521A (zh) 2024-06-28
PE20241338A1 (es) 2024-07-03
AU2022358998B2 (en) 2025-09-11
AU2025242229A1 (en) 2025-10-23
AU2022358998A1 (en) 2024-04-11
IL311681A (en) 2024-05-01
WO2023057879A1 (en) 2023-04-13
ECSP24033949A (es) 2024-06-28

Similar Documents

Publication Publication Date Title
JP5845172B2 (ja) 高および低用量薬物の組み合わせを含む口腔内崩壊錠組成物
ES2739888T3 (es) Composiciones y comprimidos farmacéuticos con recubrimiento compresible y métodos de fabricación
US7915247B1 (en) Methods of use of fenofibric acid
US20060105038A1 (en) Taste-masked pharmaceutical compositions prepared by coacervation
US20100233278A1 (en) Rapidly disintegrating solid preparation
CA2870868C (en) Orally disintegrating tablet and production process therefor
US20250228833A1 (en) Methods and compositions for treating agitation
JP2009114113A (ja) 口腔内崩壊錠及びその製造方法
US20150202226A1 (en) Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2008119033A1 (en) Pharmaceutical compositions comprising an active substance from the substituted benzhydrylpiperazine family
JP2019147844A (ja) 有効性が増加したアスピリン製剤
US20190111059A1 (en) Compositions and methods for treating autism spectrum disorder
KR101506607B1 (ko) 세팔로탁신 경구 제형
AU2025242229A1 (en) Methods and products for treating subjects with autism spectrum disorders
US20060153925A1 (en) Novel solid pharmaceutical composition comprising amisulpride
US11179331B1 (en) Oral soluble film containing sildenafil citrate
JP6061924B2 (ja) 口腔内分散性製剤
US20130143912A1 (en) Sublingual zolpidem formulations
EP2770978B1 (en) Anti-flush compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251118

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260512